ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.

Trial Details

NCT ID

NCT07318389

Phase

EARLY_PHASE1

Sponsor

M.D. Anderson Cancer Center

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

SOC (Standard of care)
Bevacizumab
Cetuximab
Panitumumab
FOLFIRI
FOLFOX

Locations (sample)

Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

Eligibility Criteria
The participant has a histologically or cytologically confirmed diagnosis of colorectal cancer.
Confirmation of non-MSI-H/pMMR status.
Tumor that is measurable as per RECIST v1.1 and biopsy able, defined as lesion/tumor that can be biopsied without undue risk.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →